growth10 min read
Dario Amodei: How He Grew Anthropic to $30B ARR in 5 Years
Read: Dario Amodei: How He Grew Anthropic … →
Oura spent seven quiet years on a finger-worn sensor bet, got one borrowed-authority moment in the 2020 NBA bubble, then a subscription pivot rewrote the math — reaching $11B.
| Date | Milestone | Valuation |
|---|---|---|
| Sep 2015 | Kickstarter closes — $651,803 from 2,383 backers | — |
| Mar 2022 | 1 million rings sold | $2.55B |
| Dec 2024 | Series D — 2024 revenue "doubled" to ~$500M | $5.2B |
| Sep 2025 | 5.5M rings sold disclosed | — |
| Oct 2025 | Series E — $900M raised | $11B |
Oura disclosed that 2024 revenue roughly doubled to about $500M and that the company was profitable. By late 2025 CEO Tom Hale told CNBC the company was tracking past $1B in 2025 revenue and guided toward roughly $2B in 2026. By December 2024 Oura had around 2 million paying subscribers — roughly $144M in annual subscription revenue against about $390M in hardware — a roughly 30/70 software-to-hardware split that public hardware comparables do not have.
Oura's first structural advantage was a contrarian hardware bet. The three founders — Petteri Lahtela, Markku Koskela, and Kari Kivelä — came out of the Oulu sensor cluster in Northern Finland (Polar, Nokia). The decision that mattered: finger-worn, not wrist-worn.
In 2013-2014 that was counterintuitive. The Apple Watch launched in April 2015, five months before Oura's Kickstarter, and Fitbit owned the tracker market — the wrist was the assumed form factor. Going to the finger meant a better PPG signal with less motion artifact, 24/7 wear including overnight, a battery that lasts 7-plus days instead of needing a nightly charge, and a discreet jewelry-like aesthetic. It also meant a smaller battery, harder manufacturing, and no display. Those trade-offs took two product generations to resolve — Gen 1 shipped late, and Gen 2 launched at Slush in November 2017 to about 10,000 units.
The bet bought Oura roughly a decade of unchallenged territory. Samsung's Galaxy Ring (2024) was the first major-platform competitor, and even after it shipped, Oura still held an estimated 80 percent of the smart-ring market. Sleep is a wedge no Apple Watch can defeat — a device that needs nightly charging structurally cannot track the night.
On June 23, 2020, the NBA — restarting its season inside a Disney World quarantine bubble — deployed roughly 2,000 Oura Rings to players and essential staff for COVID screening via skin temperature, heart rate, and HRV. The rings were optional; most players opted in. The story went to the NYT, ESPN, CBS, CNBC, and Sports Illustrated — tens of millions of impressions, none of them paid.
It landed because the ring was already credible. UCSF's TemPredict study, started in March 2020, had recruited more than 63,000 Oura wearers and would later show the algorithm flagging COVID 2.75 days before symptoms with 82 percent sensitivity. The NBA partnership was not speculative — it had a research foundation, and a finger-worn device fits inside a basketball game in a way a chest strap does not. UFC, NASCAR, the WNBA, the Seattle Mariners, and a Department of Defense pilot all followed within twelve months.
The NBA bubble is the catalyst that converted seven years of product credibility into mainstream brand awareness in a single news cycle. The earlier work made Oura a credible candidate for the role; the role made it a household name.
— from the Oura growth-story teardown
On October 26, 2021, Gen 3 launched at $299 — with most features now behind a $5.99/month membership. The reaction was immediate and angry: Reddit threads, TechCrunch reviews, Wired write-ups. Oura had spent six years selling lifetime feature access on one hardware payment, and now the same hardware required ongoing rent.
The math was clean. A $299 ring sold once is $299 of revenue. A $299 ring plus a $5.99/month subscription kept for 24 months is $443 — a 48 percent lift on lifetime value. Across millions of units, that is the difference between a struggling Fitbit and a software-margin business. Crucially, the timing was banked trust: Gen 1 and Gen 2 owners had years of free use behind them before membership ever appeared.
The pivot also reset the investor narrative — from "Finnish ring maker" to "subscription health platform." That reframing is what justified the Series D at $5.2B and the Series E at $11B — valuations a hardware-multiples lens could never reach.
The playbook is real, but three preconditions made it available to Oura and not to most hardware companies.
You need a category whose physiology validates the form factor. Finger-PPG produces cleaner sleep and HRV signals than wrist-PPG — that is a physical fact, not a marketing claim, and it is what let the form-factor bet survive a decade of incumbents. Most hardware bets do not have a physiological reason on their side.
Patient capital is rare, and Oura had Finnish patient capital. Lifeline Ventures backed Oura from 2015 and stayed through Series E. US investors do not typically tolerate seven-year gestation periods at sub-unicorn valuations; Finland's investor base does. Strip that, and the slow-burn arc is far harder to fund.
The inflection moment was luck. The NBA bubble does not happen without a pandemic. Oura got an inflection most consumer-hardware companies never get — and while it landed because UCSF research and pro-sports relationships were already in place, you cannot schedule a public-health emergency. Subscription on hardware also only works when the device produces ongoing data worth interpreting; most consumer hardware cannot justify a recurring fee and should not try. Note too that the federal channel was not a clean win: the $96M DoD contract awarded in late 2024 was unexpectedly cancelled in March 2025.
This case study is part of GrowthHunt's growth teardown series. For the software-speed contrast to Oura's 13-year hardware arc, see the Lovable teardown or the Cursor teardown. Track the fastest-growing companies live on GrowthHunt Velocity.
Six free tools are live right now — no waitlist, no card, just click in.
Explore the live tools →